Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 8 | Allergy, Asthma & Clinical Immunology

Fig. 8

From: Anti-asthmatic miR-224-5p inhibits the FHL1/MAPK pathway to repress airway smooth muscle cell proliferation in a murine model of asthma-like airway inflammation

Fig. 8

MiR-224-5p blocks the MAPK pathway activation by inhibiting FHL1 in vivo. Asthmatic mice were treated with lentivirus harboring miR-224-5p-agomir/NC-agomir or in combination with lentivirus harboring oe-FHL1/oe-NC. A Expression of miR-224-5p, FHL1, ERK, p38MAPK, and JNK in lung tissues of asthmatic mice determined by RT-qPCR. B Protein levels of FHL1, ratio of p-ERK/ERK, ratio of p-p38MAPK/p38MAPK, and ratio of p-JNK/JNK in lung tissues of asthmatic mice determined by Western blot analysis. C Protein expression of p-ERK, p38MAPK, and p-JNK in lung tissues of asthmatic mice detected by immunohistochemical analysis. n = 10 mice for each treatment. * p < 0.05 compared with asthmatic mice treated with lentivirus harboring NC-agomir. # p < 0.05 compared with asthmatic mice treated with lentivirus harboring miR-224-5p-agomir + oe-NC

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us